Dr. Kevin Scanlon

Bio

Dr. Kevin Scanlon is a seasoned leader in life sciences, with a career spanning academic medicine, executive roles in biotech and pharma, and active angel investing. Recognized by LA Techweek for his impact on the Los Angeles tech and business landscape, he served as Chairman of the Pasadena Angels, where nearly 100 investors funded over 50 companies during his tenure. Dr. Scanlon has led four biotech companies as CEO, including Melanoma Diagnostics, acquired by Myriad Genetics. At Berlex-Schering AG, he oversaw global genomic and oncology programs across the US, Europe, and Asia. His academic credentials include being a Leukemia Society Scholar, recipient of the Paul Martini Medical Research Prize (Germany), and co-founding editor of Cancer Gene Therapy (Nature Publishing Group). He has served as President of the International Society of Cell and Gene Therapy and authored 139 peer-reviewed papers, nine medical books, and seven U.S. patents. Dr. Scanlon is also the author of The Hybrid Entrepreneur.